Stockscreener 앱 받기
2.06
1.23%
0.025
시간 외 거래:
2.06
전일 마감가:
$2.035
열려 있는:
$1.94
하루 거래량:
1,257
Relative Volume:
0.14
시가총액:
$13.26M
수익:
$105.38M
순이익/손실:
$17.78M
주가수익비율:
0.7715
EPS:
2.67
순현금흐름:
$-50.48M
1주 성능:
+3.52%
1개월 성능:
+3.00%
6개월 성능:
-32.24%
1년 성능:
-32.68%
1일 변동 폭
$1.94
$2.11
1주일 범위
$1.9249
$2.14
52주 변동 폭
$1.46
$4.10
Mei Pharma Inc Stock (MEIP) Company Profile
명칭
Mei Pharma Inc
전화
858-369-7100
주소
11455 EL CAMINO REAL, SAN DIEGO, CA
MEIP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MEIP
Mei Pharma Inc
|
2.06 | 13.26M | 105.38M | 17.78M | -50.48M | 2.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Mei Pharma Inc Stock (MEIP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-07-23 | 다운그레이드 | Laidlaw | Buy → Hold |
| 2022-03-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-03-25 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-03-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-02-03 | 개시 | Jefferies | Buy |
| 2020-09-22 | 개시 | Alliance Global Partners | Buy |
| 2020-05-29 | 개시 | SunTrust | Buy |
| 2018-12-20 | 개시 | H.C. Wainwright | Buy |
| 2018-07-27 | 업그레이드 | Stifel | Hold → Buy |
| 2018-07-13 | 개시 | SunTrust | Buy |
| 2016-04-18 | 재확인 | Wedbush | Neutral |
| 2015-03-23 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2014-12-18 | 재확인 | ROTH Capital | Buy |
| 2014-10-16 | 재확인 | ROTH Capital | Buy |
| 2014-07-08 | 재개 | Brean Capital | Buy |
| 2013-10-22 | 재확인 | Stifel | Buy |
| 2013-04-15 | 개시 | Stifel | Buy |
모두보기
Mei Pharma Inc 주식(MEIP)의 최신 뉴스
A new MEI study highlights the importance of micro-entrepreneurs in supplying drinking water to poorer neighbourhoods in Ivory Coast - GlobeNewswire Inc.
10 Best NASDAQ Stocks to Buy According to Billionaires - Insider Monkey
MEI Pharma (NASDAQ:MEIP) Now Covered by StockNews.com - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
StockNews.com Initiates Coverage on MEI Pharma (NASDAQ:MEIP) - Defense World
Follicular Lymphoma Treatment Market 2034: EMA, PDMA, FDA - openPR.com
Follicular Lymphoma Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Prevalence, Revenue, Statistics and Companies by DelveInsight - The Globe and Mail
11 Best Internet Retail Stocks to Buy According to Analysts - Insider Monkey
MEI Pharma (NASDAQ:MEIP) Stock Passes Below Two Hundred Day Moving Average – Here’s What Happened - Defense World
MEI Pharma stock hits 52-week low at $1.83 amid market challenges - Investing.com
MEI Pharma stock hits 52-week low at $1.83 amid market challenges By Investing.com - Investing.com South Africa
MEI Pharma (NASDAQ:MEIP) Coverage Initiated at StockNews.com - Defense World
MEI PHARMA INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus
Follicular Lymphoma Market to Reach New Heights in Growth - openPR.com
Follicular Lymphoma Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Roche, BeiGene, Kite Pharma, Incyte Corp, AstraZeneca, MEI Pharma, Novartis, Innovent Biologics, Regeneron - Barchart.com
Virtu Financial LLC Purchases Shares of 10,744 MEI Pharma, Inc. (NASDAQ:MEIP) - Defense World
MEI Pharma (NASDAQ:MEIP) Now Covered by Analysts at StockNews.com - The AM Reporter
StockNews.com Begins Coverage on MEI Pharma (NASDAQ:MEIP) - Defense World
MEI Pharma stock hits 52-week low at $2.27 amid market challenges - Investing.com Australia
MEI Pharma (NASDAQ:MEIP) Coverage Initiated by Analysts at StockNews.com - Defense World
MEI Pharma stock hits 52-week low at $2.28 amid market challenges - Investing.com Australia
MEI Pharma stock hits 52-week low at $2.28 amid market challenges By Investing.com - Investing.com South Africa
MEI Pharma, Inc. to Host Earnings Call - ACCESS Newswire
10 Cheap Chinese Stocks to Buy Now - Insider Monkey
11 Best Undervalued Stocks to Invest in Now - Insider Monkey
The Polycythemia Vera Market Landscape Heats Up Amid Rising Competition Among Pharma Companies | DelveInsight - The Malaysian Reserve
C-COM Antenna Receives Eutelsat Type Approval - The Globe and Mail
Marginal Zone Lymphoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Alarm.com (ALRM) Q4 Earnings: What To Expect - The Globe and Mail
Why Tight Corporate-U.S. Treasury Yield Spreads Signal Good News for Ag Markets Prices - The Globe and Mail
MEI Pharma Reports Increased Losses Amid Strategic Shift - TipRanks
MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position - BioSpace
MEI Pharma Inc. (MEIP) reports earnings - Quartz
MEI Pharma, Inc. SEC 10-Q Report - TradingView
MEI Pharma's Financial Update: $23.7M War Chest Fuels Strategic Transformation - Stock Titan
Geriatric Population And Unmet Healthcare Needs Fuel Growth In Acute Myeloid Leukemia Market: A Key Driver ... - WhaTech
Malt Lymphoma Pipeline 2024: Detailed Clinical Trials - openPR
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives $43.60 Average Target Price from Analysts - Defense World
No Headlines, No Problem: Why Technical Analysis Still Moves Stocks - The Globe and Mail
Layoff Tracker: Viracta, X4 and BMS Detail Current, Upcoming Cuts - BioSpace
Protein Bar Launch in Convenience Channel, Sending Shares of this MicroCap Higher - The Globe and Mail
MEI Pharma (NASDAQ:MEIP) Earns Buy Rating from Analysts at StockNews.com - Defense World
3 Easy Ways to Build Up Your Portfolio in 2025 - The Globe and Mail
Scientist pleads guilty to stealing trade secrets for Chinese pharma company - Fox28 Savannah
Kimberly-Clark: A Regal Opportunity in This Dividend King - The Globe and Mail
ROSEN, A LEADING LAW FIRM, Encourages Infinity Pharmaceuticals, - GuruFocus.com
Will PepsiCo Hike Its Dividend Soon?Looks LikelyValue Investors Love the Stock - The Globe and Mail
Mei Pharma Inc (MEIP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):